TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vilanterol on Methacholine Challenge Results

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* men and women aged 18 or older~* stable mild-to-moderate asthma~* baseline methacholine PC20 less than or equal to 8mg/mL~* FEV1 greater than or equal to 65% of predicted~Exclusion Criteria:~* Use of long-acting anticholinergic or long-acting beta2 agonist within 30 days of study~* pregnant or nursing~* diabetes~* hypokalemia~* cardiovascular, prostate, kidney, or urinary retention problems~* lactose-intolerant~* allergy-induced asthma symptoms or upper respiratory tract infection within four weeks of study~* current smokers~* past smokers with smoking history \>10 pack years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vilanterol (Type: EXPERIMENTAL): Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
- Fluticasone (Type: EXPERIMENTAL): Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Lactose powder inhaled through Ellipta® inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent~* Able to comply with study procedures~* History of enteric or idiopathic hyperoxaluria and at least one calcium oxalate kidney stone~* Hyperoxaluria \>36mg of oxalate/24-hr~* May be taking drugs for the prevention of stone disease as long as there have been no changes in these medications for at least 3 months~Exclusion Criteria:~* Uric acid ≥1.5g/24-hr~* Estimated glomerular filtration rate of \< 60 mL/min~* Positive results from drug urine screen~* Requires daily vitamin C (defined as \>10 days of \>300 mg/day)~* Diagnosis of hypercalcemia or hypothyroidism~* Obstructive uropathy, chronic urosepsis, renal failure, renal tubular acidosis, primary hyperparathyroidism, primary hyperoxaluria, pure uric acid and cystine stones, and/or medullary sponge kidney.~* Auto-immune disorder requiring high dose steroids or other immunosuppressant drugs.~* Subjects who are pregnant. Women of childbearing potential must have a negative pregnancy test prior to enrollment and must practice approved methods of birth control during the trial~* History of cancer diagnosis except for within the past 5 years excluding dermal squamous and/or basal cell carcinoma or cervical carcinoma in situ.~* Taken investigational compound within 30 days prior to the first day of the study~* Treatment with cholestyramine~* Average daily dietary intake of \<75 mg oxalate per day calculated from diet recalls

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALLN-177 (Type: EXPERIMENTAL): Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female patients~* 18-45 years~* ASA physical status I-II~* scheduled for FESS operations~Exclusion Criteria:~* uncontrolled hypertension~* cerebrovascular disorders~* coagulation disorders~* cardiovascular diseases~* renal impairment~* liver impairment~* history of allergic reaction to any of the study medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- group N (Type: EXPERIMENTAL): Patients in this group will receive Nitroglycerin infusion for deliberate hypotension at a rate of 0.5-2 μg /kg/min .
- group L (Type: ACTIVE_COMPARATOR): Patients in this group will receive Labetalol infusion for deliberate hypotension at a rate of be 0.5-2 mg/kg/h .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Diagnosis of peripheral primitive neuroectodermal tumor, including peripheral neuroepithelioma or Askin tumor OR Diagnosis of localized or metastatic Ewing's sarcoma, including the following: Unresectable or metastatic small cell osteosarcoma Unresectable or metastatic other nonrhabdomyosarcomatous soft-tissue sarcomas Unresectable or metastatic other non-osteosarcomatous bone sarcomas Desmoplastic small round-cell tumor Metastatic or non-metastatic Wilms' tumor Immunocytochemistry, electron microscopy, and/or chromosomal analysis may be required to rule out other small round cell neoplasms~PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified~PRIOR CONCURRENT THERAPY: Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Otherwise healthy male subjects age 45 years or older with or without erectile dysfunction.~* Body Mass Index (BMI) of 17.5 to 32.5 kg/m2.~* Signed Informed Consent.~Exclusion Criteria:~* Evidence or history of clinically significant abnormalities~* Have baseline orthostatic hypotension~* Positive drug screen, excessive alcohol and tobacco use

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sildenafil ODT tablet 50 mg, Fasted (Type: ACTIVE_COMPARATOR): Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
- Sildenafil ODT tablet 50 mg, Fed (Type: EXPERIMENTAL): Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Adenoviral Patient Infected Days

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Patients will be 18 years and older.~* Duration of pink eye symptoms: No more than 4 days in first affected eye Positive immunoassay test AdenoPlus(TM) for presence of adenovirus.~* Sex: Pink eye {adenoviral conjunctivitis (Ad-Cs)} occurs with equal prevalence in males and females, therefore we will recruit both genders.~* Race/Ethnicity: Individuals of all races and ethnicities will be invited to participate in this study. Patient recruitment will reflect the distribution of race/ethnicity demographics for the patient population specific to each study site.~Exclusion Criteria:~* Patients with history of herpes simplex infection or corneal ulceration~* Eye surgery in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Betadine 5% (Type: ACTIVE_COMPARATOR): One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.
- Artificial Tears (Type: PLACEBO_COMPARATOR): One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* An intact maxillary dental arch suitable for the retention of the palatal appliance and an intact mandibular dental arch - subjects may have fixed bridges replacing missing teeth~* No current active caries or periodontal disease that may compromise the study or the health of the subjects~* A gum base stimulated whole saliva flow rate greater than or equal to 0.8 mL/minute and an unstimulated whole saliva flow rate greater than or equal to 0.2 mL/minute~Exclusion Criteria:~* Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Test Dentifrice + Test Mouth Rinse (MR) (Type: EXPERIMENTAL): Test fluoride dentifrice and test fluoride MR
- Test Dentifrice + Sterile Water Rinse (Type: EXPERIMENTAL): Test fluoride dentifrice and sterile water rinse
- Placebo Dentifrice + Test MR (Type: EXPERIMENTAL): Placebo dentifrice and test fluoride rinse
- Reference Dentifrice + Sterile Water Rinse (Type: ACTIVE_COMPARATOR): Marketed fluoride dentifrice with sterile water rinse
- Placebo Dentifrice + Sterile Water Rinse (Type: PLACEBO_COMPARATOR): Placebo dentifrice and sterile water rinse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers, 18-60 years~* Seronegative for one or two of the applied vaccine strains~* Low antibody titres for H1N1v~* Written informed consent to participate in this study~* For female volunteers of childbearing potential, provision of a history and current use of reliable contraceptive practices~Exclusion Criteria:~* Acute febrile illness (\>37.3°C)~* Signs of acute or chronic upper or lower tract respiratory illnesses~* History of severe atopy~* Seasonal influenza vaccination in 2008/2009 and/or later seasons and/or pandemic influenza vaccination at any time~* Fever ≥38.0°C in the time period between the pre-screening visit and day 1~* Known increased tendency of nose bleeding~* Volunteers with clinically relevant abnormal paranasal anatomy~* Volunteers with clinically relevant abnormal laboratory values~* In female volunteers of childbearing potential, a positive urine pregnancy test~* Simultaneous treatment with immunosuppressive drugs incl. Corticosteroids (≥2 weeks) within 4 weeks prior to study medication application~* Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological, skin, endocrine, neurological or immunological diseases~* History of leukaemia or cancer~* HIV or Hepatitis B or C seropositivity~* Volunteers who underwent rhino or sinus surgery, or surgery of another traumatic injury of the nose within 30 days prior to application of study medication~* Volunteers who have received antiviral drugs, treatment with immunoglobulins or blood transfusions, or an investigational drug within 4 weeks prior to study medication application~* Volunteers who have received anti-inflammatory drugs 2 days prior to study medication application~* Volunteers who are not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- SPGNH buffer (Type: PLACEBO_COMPARATOR): SPGNH buffer administration by liquid nasal spray
- GHB16L2 (Type: EXPERIMENTAL): Dose level \~7.0 log10 fTCID50/strain/person

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yellow Fever Vaccine in Patients With Rheumatic Diseases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatic disease under low immunosuppression (hydroxychloroquine, sulfasalazine or methotrexate plus prednisone up to 7,5mg/day or leflunomide plus prednisone up to 7,5mg/day),~* Resident in high risk área for Yellow Fever~Exclusion Criteria:~* Active disease~* Primary immunodeficiency~* History of anaphylactic response to vaccine components or egg allergy~* Living outside the risk area~* Do not meet criteria for low immunosuppression~* History of previous immunization with the yellow fever vaccine~* History of live virus vaccine up to 4 weeks before~* Individuals who do not agree to participate in the study and/or whose parents do not agree to participate in the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Rheumatic diseases patients (Type: ACTIVE_COMPARATOR): Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
- Healthy controls (Type: ACTIVE_COMPARATOR): Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40-75 years,~* BMI 25-35 kg/m2,~* WHO criteria for type 2 diabetes fasting plasma glucose\>=7.0 mmol/l on at least 2 separate occasions,~* C-peptide\>0.2 nmol/l~Exclusion Criteria:~* plasma glucose \< 6.1 or \>10 mmol/l after the screening period~* cardiac heart failure~* diagnosed coronary heart disease~* severe aortic, mitral or tricuspidal valve disease~* blood pressure \> 160/ 100 mg Hg~* any previous or present hepatic (GT \>100, alanine amino transferase \>3 x upper limit of the reference range) or renal (S-creatinine \> 130) disease~* pregnancy or lactation~* proliferative retinopathy~* microalbuminuria~* subjects with history of lactate acidosis~* symptomatic polyneuropathy~* antidiabetic medication~* changes in antihypertensive medication or beta-blockers in medication~* metal objects in region of imaging~* anemia with Hb \< 100 in mean or \< 90 in women~* oral corticosteroid treatment

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo, 2 tablets per day
- Metformin (Type: ACTIVE_COMPARATOR): 500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day
- Rosiglitazone (Type: ACTIVE_COMPARATOR): 2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients of either gender aged 18+ years.~2. Diagnosis of chronic cerebral ischemia (CCI) based on the clinical history of underlying vascular disease(atherosclerosis and/or arterial hypertension) and neurological signs.~3. Unchanged basic therapy of CCI and underlying vascular disease for a previous 3 month.~4. Signed informed consent form.~Exclusion Criteria:~1. Other neurological diseases.~2. Any known allergy to/intolerance of any constituent of the medication.~3. Pregnancy, breast-feeding.~4. Participation in other clinical trials for 3 months prior to enrollment in this study.~5. The patient is related to the research personnel of the investigative sites that are directly involved in the study, or is the immediate relative of the investigator, or the employee of OOO NPF Materia Medica Holding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Divaza (Type: None): Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Patients, aged 18 years or over, with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.~* Baseline testosterone \>1.5 ng/mL.~* Life expectancy of at least 12 months.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- degarelix 240/160 mg (Type: EXPERIMENTAL): Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
- degarelix 240/80 mg (Type: EXPERIMENTAL): Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
- Leuprolide 7.5 mg (Type: ACTIVE_COMPARATOR): Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed, adenocarcinoma of the prostate, clinical stage T1c-T3b, N0, M0.~2. Patient will have clinically negative nodes as established by imaging (pelvic computed tomography (CT), magnetic resonance imaging (MRI)).~3. The patient will be clinically M0.~4. Zubrod status 0-1.~5. No prior pelvic or prostate radiation or chemotherapy for prostate cancer; induction hormonal therapy beginning ≤ 120 days prior to registration is acceptable.~6. One of the following combinations of factors:~   Clinical stage T1c-T2c, Gleason score 2-6 and prostate-specific antigen (PSA) \>10 but ≤ 20 Clinical stage T3a-T3b, Gleason score 2-6 and PSA ≤ 20 Clinical stage T1c-T3b, Gleason score 7-10 and PSA ≤ 20~7. Patients must sign a study-specific consent form prior to registration.~Exclusion Criteria:~1. Stage T4 disease.~2. Lymph node involvement (N1).~3. Evidence of distant metastases (M1).~4. Radical surgery for carcinoma of the prostate.~5. Previous hormonal therapy beginning \> 120 days prior to registration.~6. Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.~7. Prior transurethral resection of the prostate (TURP).~8. Prior invasive malignancy(except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (For example, carcinoma in situ of the oral cavity or bladder are permissible).~9. Hip prosthesis.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- External Beam Radiotherapy and High Dose brachytherapy boost (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete